由于其合成大麻素ART27.13的全资格研究, 阿尔特洛生物科学股价升了50%. Artelo Biosciences shares surged 50% after announcing a fully funded glaucoma trial for its synthetic cannabinoid ART27.13.

在2026年3月18日,Artelo Biosciences股价升超过50%,至7.03美元.此前该公司宣布与贝尔法斯特健康和社会护理信托基金共同开展一项全资临床研究,以评估其合成大麻素ART27.13治疗青光眼的效果. Artelo Biosciences shares jumped over 50% to $7.03 on March 18, 2026, after announcing a fully funded clinical study with the Belfast Health and Social Care Trust to evaluate its synthetic cannabinoid ART27.13 for glaucoma. 这项由英国眼光病和美国卫生研究院研发部门支持的试验将评估该药物降低内压力的能力,预计在2026年第二季度就会招收第一名患者. The trial, supported by Glaucoma UK and the HSC R&D Division, will assess the drug’s ability to reduce intraocular pressure and is expected to enroll its first patient in the second quarter of 2026. 该化合物向外围大麻素受体, 影响眼睛压力而无中枢神经系统副作用. The compound targets peripheral cannabinoid receptors to influence eye pressure without central nervous system side effects. 这项研究标志着Artelo在眼病领域的扩张迈出了关键一步, 预计到2033年市场将增长至163亿美元. The study marks a key step in Artelo’s expansion into glaucoma, a market projected to grow to $16.3 billion by 2033. 随着最近的逆向股票分割,库存激增. 此次增加是在癌症相关厌食症第二阶段试验和欧洲专利延期至2041年期间取得积极进展的情况下出现的. The stock surge follows a recent reverse stock split and comes amid positive developments in a separate Phase 2 trial for cancer-related anorexia and a European patent extension through 2041.